Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Aarhus University currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being handled by SZPERKA, MICHAEL EDWARD, who serves as the busiest examiner with 1 pending action. The prosecution profile is highly focused, involving only 1 distinct examiner and 1 distinct art unit. This singular point of contact defines the current active patent landscape for the university at the office.
With 1 pending office action assigned to SZPERKA, MICHAEL EDWARD, the university's prosecution is concentrated under a single examiner. This arrangement within the Biotechnology & Pharmaceuticals sector means that the outcome of the current filing depends entirely on the review within 1 distinct art unit. For the university, having 1 distinct examiner simplifies the management of its pending matters but also means there is no diversification across different examiners. The presence of 1 pending action for the busiest examiner confirms that the entire active portfolio is currently being reviewed by the same individual.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZPERKA, MICHAEL EDWARD | 1 | 62.6% | +37.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18708110 | METHODS FOR TREATING OR PREVENTING VIRAL INFECTION | SZPERKA, MICHAEL EDWARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18708110 | METHODS FOR TREATING OR PREVENTING VIRAL INFECTION | SZPERKA, MICHAEL EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18708110 | METHODS FOR TREATING OR PREVENTING VIRAL INFECTION | SZPERKA, MICHAEL EDWARD | 1641 | §102§103§112 | Non-Final OA | — | Pending | May 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAarhus University has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael Edward Szperka has the most, with 1 of Aarhus University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
